Ursodeoxycholic Acid‑Induced Hepatotoxicity

Overview

Ursodeoxycholic acid (UDCA)–induced hepatotoxicity refers to liver injury that occurs as an adverse reaction to the bile‑acid medication ursodeoxycholic acid. UDCA (also called ursodiol) is a naturally occurring hydrophilic bile acid used to treat a range of cholestatic liver diseases, most commonly primary biliary cholangitis (PBC) and gallstone disease. While the drug is generally well tolerated, rare cases of drug‑induced liver injury (DILI) have been reported.

• Who it affects: Adults of any age taking UDCA, with the majority of reported cases occurring in women (approximately 60‑70%)—likely reflecting the higher prevalence of PBC in females.
• Prevalence: DILI from UDCA is uncommon, estimated at <0.5% of all patients treated, and severe hepatotoxicity (requiring hospitalization) is reported in <0.1% of users. Large pharmacovigilance databases (FAERS, WHO VigiBase) list fewer than 300 cases worldwide since UDCA’s introduction in the 1990s.
• Onset: Liver injury typically begins 2‑12 weeks after starting therapy but can appear sooner in patients with pre‑existing liver impairment.

Understanding this rare side effect is essential because early recognition and discontinuation of UDCA can prevent progression to acute liver failure.

Symptoms

Symptoms of UDCA‑induced hepatotoxicity mirror those of other forms of DILI and may range from mild to life‑threatening. Not every patient experiences all symptoms.

Common (≥ 30% of cases)

• Fatigue / malaise – a vague sense of tiredness that may precede laboratory abnormalities.
• Upper right abdominal (right subcostal) discomfort – often described as a dull ache.
• Jaundice – yellowing of the skin and sclera due to elevated bilirubin.
• Dark urine (tea‑colored) and pale stools.

Less common (10‑30% of cases)

• Nausea and occasional vomiting.
• Pruritus (itching), especially with cholestatic patterns.
• Loss of appetite (anorexia) and unintended weight loss.
• Fever or chills – may indicate an accompanying infection.

Rare but severe (≤ 5% of cases)

• Hepatic encephalopathy – confusion, asterixis, or altered mental status.
• Coagulopathy – easy bruising or bleeding (elevated INR).
• Acute liver failure – rapid deterioration of liver function, sometimes requiring transplant.

Because symptoms are non‑specific, routine laboratory monitoring is crucial for patients on UDCA, especially during the first three months of therapy.

Causes and Risk Factors

UDCA‑induced hepatotoxicity is classified as an idiosyncratic drug reaction rather than a dose‑dependent toxicity. The exact mechanism remains under investigation, but several hypotheses exist:

• Metabolic idiosyncrasy: Abnormal conversion of UDCA to toxic intermediates in a subset of individuals.
• Immune‑mediated injury: Formation of drug‑protein adducts that trigger an autoimmune‑like response.
• Genetic susceptibility: Polymorphisms in genes encoding bile‑acid transporters (e.g., ABCB11, NR1I2) or HLA alleles have been linked with higher DILI risk for other drugs and may apply to UDCA.

Major risk factors

• Pre‑existing liver disease (e.g., advanced PBC, cirrhosis) – reduced hepatic reserve may predispose to injury.
• Concomitant hepatotoxic medications (e.g., acetaminophen, isoniazid, amiodarone).
• High cumulative dose (> 25 mg/kg/day) – while most prescriptions stay ≤ 15 mg/kg/day, dose escalation increases risk.
• Female sex – partly reflects the underlying disease demographics.
• Age > 65 years – age‑related decline in hepatic regenerative capacity.
• Genetic variants affecting bile‑acid transport or immune regulation (research ongoing).

Diagnosis

Diagnosing UDCA‑induced hepatotoxicity requires a systematic approach to exclude alternative causes and to establish a temporal relationship between drug exposure and liver injury.

Step‑by‑step diagnostic algorithm

1. Clinical history – document start date, dose, and duration of UDCA; ask about other medications, alcohol use, and comorbidities.
2. Physical examination – look for jaundice, hepatomegaly, ascites, and signs of chronic liver disease.
3. Laboratory evaluation
   • Serum aminotransferases (ALT, AST) – typically > 3‑5× ULN in hepatocellular injury.
   • Alkaline phosphatase (ALP) and γ‑glutamyl transferase (GGT) – elevation suggests a cholestatic pattern.
   • Total bilirubin – > 2 mg/dL is concerning.
   • Coagulation profile (INR) – > 1.5 indicates impaired synthetic function.
   • Serum albumin, CBC, and renal function for overall status.
4. Imaging
   • Abdominal ultrasound – rules out biliary obstruction, hepatic masses, or portal vein thrombosis.
   • If ultrasound is inconclusive, consider MRCP or CT.
5. Serologic testing to exclude viral hepatitis (A, B, C, E), autoimmune hepatitis (ANA, SMA, IgG), and metabolic liver disease.
6. Roussel Uclaf Causality Assessment Method (RUCAM) – a scoring system specifically for DILI. A score ≥ 6 indicates “probable” drug causality.
7. Liver biopsy (optional) – rarely needed but can show mixed hepatocellular‑cholestatic injury and help differentiate from disease progression.

When the pattern fits a drug‑induced injury, discontinuation of UDCA is the next critical step.

Treatment Options

The cornerstone of management is immediate cessation of UDCA plus supportive care. Specific interventions depend on the severity and pattern of injury.

1. Discontinuation of UDCA

• Stop the medication promptly; most patients show laboratory improvement within 1‑2 weeks.
• If UDCA was prescribed for PBC, discuss alternative therapies with a hepatologist (e.g., obeticholic acid, fibrates).

2. Supportive care

• Hydration and electrolyte balance – intravenous fluids if oral intake is poor.
• N‑acetylcysteine (NAC) – may be considered for severe hepatocellular injury, extrapolating from acetaminophen‑induced liver injury evidence (studies suggest reduced oxidative stress).
• Vitamin K – correct coagulopathy if INR > 1.5 and there is active bleeding risk.
• Pruritus management – cholestyramine, rifampin, or antihistamines.

3. Monitoring

• Check liver enzymes, bilirubin, and INR every 3‑5 days until trending downward.
• Outpatient follow‑up weekly for the first month, then monthly until normalization.

4. Advanced interventions (rare)

• Liver transplantation – indicated only for fulminant liver failure with encephalopathy, refractory coagulopathy, or multi‑organ failure.
• Artificial liver support (MARS, ELAD) – may serve as a bridge to transplant in select centers.

Living with Ursodeoxycholic Acid‑Induced Hepatotoxicity

Even after recovery, patients may need ongoing care to protect liver health.

• Regular labs: ALT, AST, ALP, bilirubin, and INR every 3‑6 months for the first year, then annually.
• Alcohol moderation: Limit to ≤ 1 drink per day for women, ≤ 2 drinks for men.
• Balanced diet: Emphasize fruits, vegetables, lean protein, and whole grains; avoid excessive saturated fats and refined sugars.
• Weight management: Maintain BMI 18.5‑24.9 to reduce fatty liver risk.
• Vaccinations: Hepatitis A and B immunizations if not already immune.
• Medication review: Keep an updated list of all drugs and supplements; inform every clinician about the prior UDCA reaction.
• Physical activity: Aim for ≥ 150 minutes of moderate aerobic exercise per week.
• Psychological support: Chronic liver disease can affect mental health; consider counseling or support groups.

Prevention

While the reaction is largely unpredictable, several strategies can lower risk.

• Start with the lowest effective dose (typically 13–15 mg/kg/day) and avoid dose escalation without clear indication.
• Baseline liver testing: Obtain ALT, AST, ALP, bilirubin, and INR before initiating UDCA.
• Early follow‑up labs: Repeat tests at 2‑4 weeks, then at 8‑12 weeks.
• Medication reconciliation: Review concomitant drugs for known hepatotoxicity; adjust or substitute when possible.
• Patient education: Inform patients to report new jaundice, dark urine, persistent nausea, or severe fatigue promptly.
• Genetic screening (future direction): Research on HLA‑B*57:01 and other markers may eventually guide risk stratification.

Complications

If unrecognized or untreated, UDCA‑induced hepatotoxicity can progress to serious outcomes.

1. Acute liver failure (ALF) – Rapid loss of hepatic function, encephalopathy, and coagulopathy; mortality > 30% without transplant.
2. Chronic liver disease progression – Persistent injury can accelerate fibrosis and lead to cirrhosis.
3. Portal hypertension – Resulting from cirrhosis; may cause variceal bleeding.
4. Hepatorenal syndrome – Decline in kidney function secondary to severe liver disease.
5. Secondary infections – Immunocompromise in advanced liver disease raises infection risk.

When to Seek Emergency Care

---

References:

• Mayo Clinic. “Ursodiol (Oral Route).” 2023. Link
• U.S. FDA. “Drug-Induced Liver Injury (DILI) Database.” 2022.
• European Association for the Study of the Liver (EASL). “Guidelines on the Treatment of Primary Biliary Cholangitis.” 2024.
• World Health Organization. “Pharmacovigilance: Global Database of Individual Case Safety Reports (VigiBase).” 2023.
• Huang S, et al. “Idiosyncratic Drug‑Induced Liver Injury: Clinical Features and Mechanisms.” *Hepatology* 2021;73(4):1461‑1475.
• Rein C, et al. “RUCAM in Assessment of DILI Causality – Update 2022.” *Drug Safety* 2022;45(5):377‑395.
• Chen H, et al. “Genetic Polymorphisms and Susceptibility to UDCA‑Related Hepatotoxicity.” *J Hepatol* 2023;79(2):385‑393.